Skip Navigation

San Antonio Breast Cancer Symposium (SABCS)

  • December 10 – 14, 2019
    Henry B. Gonzalez Conference Center, San Antonio, TX

    Dana-Farber at SABCS 2019

  • Jennifer Ligibel, MD, at SABCS in 2018

  • Dana-Farber breast oncologists, surgeons, and researchers participated in the 2019 San Antonio Breast Cancer symposium. Our faculty shared results from clinical trials and recent research studies, and led a variety of conversations on improving breast cancer care.

    Catch up on Twitter: #SABCS19

    Schedule of Presentations by Dana-Farber Faculty

    As leaders in breast cancer research, physicians and scientists from Dana-Farber Cancer Institute are participating in workshops, general sessions, and forums at SABCS 2019.

    View the schedule of presentations by Dana-Farber faculty for Tuesday through Friday

    Dana-Farber Researchers Present Major Studies at SABCS

    Presentations include:

  • Dana-Farber's Eric P. Winer, MD, Explains Results of HER2CLIMB Trial
    This trial looked at a new breast cancer drug called tucatinib, combined with standard therapies.


    • Results from the phase 2 DESTINY-01 study showing a new antibody-drug conjugate helped prevent cancer progression in women with advanced HER2+ breast cancer. Details in video below:
  • Ian Krop, MD, PhD, Presents Results from the Phase 2 DESTINY-01 Study
    This study showed how a new antibody-drug conjugate helped prevent cancer progression in women with advanced HER2+ breast cancer.


    • Results from the Phase 2 ATEMPT trial exploring a less toxic therapy for early state HER2+ breast cancer. Details in video below:
  • Sara Tolaney, MD, MPH, Presents Results from the Phase 2 ATEMPT Trial
    The Phase 2 ATEMPT trial explored a less toxic therapy for early state HER2+ breast cancer.